This iPSC-derived off-the-shelf NK cell cancer immunotherapy is engineered to have novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor; an IL-15/IL-15 receptor fusion (IL-15RF); and knockdown of the CD38 gene via CRISPR/Cas9 to eliminate daratumumab-induced CD38+ immune regulatory cell depletion, which in turn increases NK cell effector activity. This evidence concerns the gene CD38 and cancer.